SnoRNAs:The promising targets for anti-tumor therapy
10.1016/j.jpha.2024.101064
- Author:
Xiaoyun HU
1
;
Wanlin CUI
;
Min LIU
;
Fangxiao ZHANG
;
Yingqi ZHAO
;
Mingrong ZHANG
;
Yuhang YIN
;
Yalun LI
;
Ying CHE
;
Xianglong ZHU
;
Yuxuan FAN
;
Xiaolan DENG
;
Minjie WEI
;
Huizhe WU
Author Information
1. Department of Pharmacology,School of Pharmacy,China Medical University,Shenyang,110122,China;Liaoning Key Laboratory of Molecular Targeted Anti-tumor Drug Development and Evaluation,Liaoning Cancer Immune Peptide Drug Engineering Technology Research Center,Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors,Ministry of Education,China Medical University,Shenyang,110122,China;Scientific Experimental Center,School of Pharmacy,China Medical University,Shenyang,110122,China
- Publication Type:Journal Article
- Keywords:
snoRNA;
Cancer;
snoRNA host gene;
Multidrug resistance;
Targeted therapy;
Tumor immune microenvironment
- From:
Journal of Pharmaceutical Analysis
2024;14(11):1588-1602
- CountryChina
- Language:English
-
Abstract:
Recently,small nucleolar RNAs(snoRNAs)have transcended the genomic"noise"to emerge as pivotal molecular markers due to their essential roles in tumor progression.Substantial evidence indicates a strong association between snoRNAs and critical clinical features such as tumor pathology and drug resistance.Historically,snoRNA research has concentrated on two classical mechanisms:2'-O-ribose methylation and pseudouridylation.This review specifically summarizes the novel regulatory mecha-nisms and functional patterns of snoRNAs in tumors,encompassing transcriptional,post-transcriptional,and post-translational regulation.We further discuss the synergistic effect between snoRNA host genes(SNHGs)and snoRNAs in tumor progression.More importantly,snoRNAs extensively contribute to the development of tumor cell resistance as oncogenes or tumor suppressor genes.Accordingly,we provide a comprehensive review of the clinical diagnosis and treatment associated with snoRNAs and explore their significant potential as novel drug targets.
